Investigational New Drugs

, Volume 19, Issue 4, pp 335–340 | Cite as

Dolastatin-10 in Metastatic Melanoma: A Phase II and Pharmokinetic Trial of the California Cancer Consortium

  • Kim Margolin
  • Jeffrey Longmate
  • Timothy W. Synold
  • David R. Gandara
  • Jeffrey Weber
  • Rene Gonzalez
  • Mary J. Johansen
  • Robert Newman
  • Tracey Baratta
  • James H. Doroshow


Dolastatin-10 is a novel pentapeptide agentoriginally isolated from the marine molluskDolabella auricularia with amechanism of antitumor activity thatinvolves the inhibition of microtubuleassembly. We performed a Phase II trial ofDolastatin-10, 400 μg/m2, inpatients with advanced melanoma who hadreceived no prior chemotherapy. Dolastatin-10 pharmokinetics wereevaluated in a subset of patients followingcourses 1 and 2. Twelve patients weretreated with a median of 2 cycles ofDolastatin-10, and no patient experiencedan objective response. The only grade >2toxicities were grade 3 neutropeniauncomplicated by infection, occurring in 4patients following the first treatmentcycle. The total systemic clearance andvolume of distribution at steady-state were2.61 ± 1.9 L/h/m2 and 28.4 ± 13 L/m2,respectively. Due toprolonged terminal elimination,Dolastatin-10 plasma concentrations ofgreater than 1 nM were sustained for 24h in all patients studied. Dolastatin-10 is unlikely to havesubstantial activity in the treatment ofmelanoma.

Dolastatin-10 metastatic melanoma pharmokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Ang KK. Adjuvant therapy for the treatment of high risk for recurrent stage II and III disease. In: DeVita, VT Jr., Hellman S, Rosenberg SA (eds) Cancer, Principles and Practice of Oncology, Vol 5. Lippincott-Raven Publishers, New York, NY, 1997, pp 1975–1979Google Scholar
  2. 2.
    Chapman P, Einhorn LH, Meyers M, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745–2751, 1999Google Scholar
  3. 3.
    Margolin K, Liu P-Y, Flaherty L, Sosman J, Unger J, Sondak V. Phase II study of BCNU, DTIC, cisplatin and tamoxifen in advanced melanoma: A Southwest Oncology Group study. J Clin Oncol 16: 664–669, 1998Google Scholar
  4. 4.
    Mitchell MS, Von Eschen KB: Phase III trial of Melacine_ melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proc Am Soc Clin Oncol 16: 494a, 1997Google Scholar
  5. 5.
    Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, Eckardt JR, Pereira C, Aronson FR: Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12: 1553–1560, 1994Google Scholar
  6. 6.
    Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16: 1752–1759, 1998Google Scholar
  7. 7.
    Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, Vuillemin E, Bazex PA, Thill L, Franks R, Auclerc G, Soubrane C, Banzet P, Weil M: Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11: 2173–2180, 1993Google Scholar
  8. 8.
    Richards JM, Gale D, Mehta N, Lestingi T: Combination chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 17: 651–657, 1999Google Scholar
  9. 9.
    Keilholz U, Goey SH, Punt CJA, Proebstle TM, Salzmann R, Scheibenbogen CD, Schadendorf D, Lienard D, Enk A, Dummer R, Hantich B, Geueke A-M, Eggermont A: Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for the Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15: 2579–2588, 1997Google Scholar
  10. 10.
    Rosenberg SA, Yang JC, Schwarzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17: 968–975, 1999Google Scholar
  11. 11.
    Pettit GR, Kamano Y, Herald CT, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems RJ: The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin-10. J Am Chem Soc 109: 6883–6885, 1987Google Scholar
  12. 12.
    Hu ZB, Gignac SM, Quentmeier H, Pettit GR, Drexler HG: Effects of dolastatins on human B-lymphocytic leukemia cell lines. Leukemia Res 17: 333–339, 1993Google Scholar
  13. 13.
    Steube KG, Grunicke D, Pietsch T, Gignac SM, Pettit GR, Drexler HG: Dolastatin-10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells. Leukemia 6: 1048–1053, 1992Google Scholar
  14. 14.
    Quentmeier H, Brauer S, Pettit GR, Drexler HG: Cytotoxic effects of Dolastatin-10 and 15 on human leukemia cell lines. Leukemia and Lymphoma 6: 245–250, 1992Google Scholar
  15. 15.
    Korsmeyer SJ: Bcl-2: an antidote to programmed cell death. Cancer Surveys 15: 105–118, 1992Google Scholar
  16. 16.
    Kalemkerian G, Ou X, Adil M, Rosati R, Khoulani MM, Madan SK, Pettit GR: Activity of Dolastatin-10 against small cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 43: 507–515, 1999Google Scholar
  17. 17.
    Haldar S, Jena N, Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507–4511, 1995Google Scholar
  18. 18.
    Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM: Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56: 1851–1854, 1996Google Scholar
  19. 19.
    Miyashita T, Harigal M, Hanada M, Reed JC: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131–3135, 1994Google Scholar
  20. 20.
    Toppmeyer DL, Slapak CA, Croop J, Kufe DW: Role of Peglacoprotein in Dolastatin-10 resistance. Biochem Pharmacol 48: 609–612, 1994Google Scholar
  21. 21.
    Pulaski L, Jedlitschky G, Leier I, Buchholz U, Keppler D: Identification of the multidrug-resistance protein (MRP) as the glutathione-s-conjugate export pump of erythrocytes. Eur J Biochem 241: 644–648, 1996Google Scholar
  22. 22.
    Tran HT, Newman RA, Beck DE, Huie R, Abbruzzese JL, Madden T: A phase I pharmokinetic/pharmacodynamic study of Dolastatin-10 in adult patients with advanced solid tumors. Proc Am Assoc Canc Res 38: 2056, 1997Google Scholar
  23. 23.
    Pitot HC, McElroy EA Jr., Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM: Phase I trial of Dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5: 525–531, 1999Google Scholar
  24. 24.
    Garteiz DA, Madden T, Beck DE, Huie WR, McManus KT, Abbruzzese JL, Chen W, Newman RA: Quantitation of Dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial. Cancer Chemother Pharmacol 41: 299–306, 1998Google Scholar
  25. 25.
    Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6: 165–175, 1978Google Scholar
  26. 26.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49–53, 1991Google Scholar
  27. 27.
    El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825, 1993Google Scholar
  28. 28.
    Poremba C, Yandell DW, Metze D, Kamanabrou D, Bocker W, Dockhorn-Dworniczak B: Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res 7: 331–339, 1995Google Scholar
  29. 29.
    Saenz-Santamaria MC, McNutt NS, Bogdany JK, Shea CR: p53 expression is rare in cutaneous melanomas. Am J Dermatopathol 17: 344–349, 1995Google Scholar
  30. 30.
    Hartmann A, Blaszyk H, Cunningham JS, McGovern RM, Schroeder JS, Helander SD, Pittelkow MR, Sommer SS, Kovach JS: Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer 29;67(3): 313–317, 1996Google Scholar
  31. 31.
    Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ: p53 gene mutation and expression in naevi and melanomas. Melanoma Res 5(2): 93–100, 1995Google Scholar
  32. 32.
    Platz A, Ringborg U, Graftstrom E, Hoog A, Lagerlof B: Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res 5(2): 101–106, 1995Google Scholar
  33. 33.
    Mirsalis JC, Schindler-Horvat J, Hill JR, Tomaszewski JE, Donohue SJ, Tyson CA: Toxicity of Dolastatin-10 in mice, rats and dogs and its clinical relevance. Cancer Chemother Pharmacol 44: 395–402, 1999Google Scholar
  34. 34.
    Bai R, Pettit GR, Hamel E: Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39: 1941–1949, 1999Google Scholar
  35. 35.
    Beckwith M, Urba WJ, Longo DL: Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst 85: 483–488, 1993Google Scholar
  36. 36.
    Madden T, Tran HT, Beck D, Huie R, Newman RA, Puusztai L, Wright JJ, Abbruzzese: Novel marine-derived anticancer agents: A phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 6: 1293–1301, 2000Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Kim Margolin
    • 1
  • Jeffrey Longmate
    • 2
  • Timothy W. Synold
    • 1
  • David R. Gandara
    • 3
  • Jeffrey Weber
    • 4
  • Rene Gonzalez
    • 5
  • Mary J. Johansen
    • 6
  • Robert Newman
    • 6
  • Tracey Baratta
    • 2
  • James H. Doroshow
    • 1
  1. 1.Department of Medical Oncology and Therapeutics ResearchCity of Hope National Medical CenterDuarteU.S.A.
  2. 2.Department of BiostatisticsCity of Hope National Medical CenterDuarteU.S.A.
  3. 3.Department of Medical OncologyUniversity of California at Davis Medical CenterSacramentoU.S.A.
  4. 4.Department of Medical OncologyUniversity of Southern California/Kenneth Norris Cancer CenterLos Angeles
  5. 5.Department of Medical OncologyUniversity of Colorado Cancer CenterDenverU.S.A.
  6. 6.Department of Experimental TherapeuticsM.D. Anderson Cancer CenterHoustonU.S.A.

Personalised recommendations